Millennium Velcade Supplement Seeks Full Approval, Second-Line Use
This article was originally published in The Pink Sheet Daily
Executive Summary
The company hopes to convert Velcade's accelerated approval for third-line use to full approval and add a second-line multiple myeloma indication based on the Phase III APEX trial, which showed a significant survival benefit.